Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Tony Wood appointed Chief Scientific Officer designate, GSK
Tony Wood appointed Chief Scientific Officer designate, GSK
Read more -
Update - GSK Consumer Healthcare
GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc
Read more -
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19
600,000 additional doses to be supplied to the US Government for distribution in Q1 2022
Read more -
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare announces US FDA approval of Apretude
Read more -
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
Read more -
Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19
GSK and Vir are committed to the ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve
Read more -
GSK and Sanofi announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of phase III trial per independent Monitoring Board recommendation
Companies intend to file booster data with regulatory authorities following the phase III results
Read more -
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment
GSK announced new data from the DREAMM-9 phase I trial and two GSK collaborative studies investigating the potential use of Blenrep.
Read more -
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
Read more -
Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant
New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv
Read more -
GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children
Gavi to provide funding for procurement and introduction of malaria vaccines into child immunisation programmes in Gavi eligible countries.
Read more -
MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab)
Conditional marketing authorisation has been granted for Great Britain and is based on Phase III data
Read more -
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
The institute aims to deepen understanding of complex diseases such as Alzheimer’s and Parkinson’s, and increase drug discovery.
Read more -
Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant
Data to be confirmed by further in vitro pseudo-virus testing
Read more -
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
$100,000 grant to be awarded to best idea submitted to Target the Future Think Tank Challenge
Read more -
GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D
Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021
Read more -
GSK showcases progress from the DREAMM clinical trial programme in multiple myeloma at the 2021 ASH Annual Meeting
11 abstracts on Blenrep will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition.
Read more -
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide
Read more -
European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases
Mepolizumab is now the only treatment approved in Europe for use in four eosinophil-driven diseases
Read more -
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Phase III IM administration data for sotrovimab.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
